Endure Bio® Technology



View the Cell publication that describes our technology.

Intestinal Transgene Delivery with Native E. coli Chassis Allows Persistent Physiological Changes

Baylee J. Russell, Steven D. Brown, Anand R. Saran, Irene Mai, Amulya Lingaraju, Nicole Siguenza, Erica Maissy, Ana C. Dantas Machado, Antonio F. M. Pinto, Yukiko Miyamoto, Alexander Richter, Samuel B. Ho, Lars Eckman, Jeff Hasty, Alan Saghatelian, Rob Knight, Amir Zarrinpar

Live bacterial therapeutics (LBT) could reverse disease by engrafting in the gut and providing persistent beneficial functions in the host. However, attempts to functionally manipulate the gut microbiome of conventionally-raised (CR) hosts have been unsuccessful, because engineered microbial organisms (i.e., chassis) cannot colonize the hostile luminal environment. In this proof-of-concept study, we use native bacteria as chassis for transgene delivery to impact CR host physiology. Native Escherichia coli isolated from stool cultures of CR mice were modified to express functional bacterial (bile salt hydrolase) and eukaryotic (Interleukin-10) genes. Reintroduction of these strains induces perpetual engraftment in the intestine. In addition, engineered native E. coli can induce functional changes that affect host physiology and reverse pathology in CR hosts months after administration. Thus, using native bacteria as chassis to “knock-in” specific functions allows mechanistic studies of specific microbial activities in the microbiome of CR hosts, and enables LBT with curative intent.